Glioblastoma is one of the most aggressive and treatment‑resistant brain cancers, with a median survival of only 12‑15 months even under optimal care. Researchers at MIT Media Lab have created an injectable nanoantenna—about one‑hundredth the width of a human hair—that can be magnetically actuated to generate localized therapeutic electric fields, killing cancer cells while sparing healthy brain tissue.
The technology, dubbed HITMAN (Highly‑Localized Electric‑field‑Induced Tumor therapy using Magnetically actuated nanoantennas), consists of a ~150 nm particle containing magnetostrictive material and a piezoelectric film. A low‑frequency magnetic field (≤200 kHz) penetrates the skull, strains the magnetostrictive component, which deforms the piezoelectric layer to produce a focused electric field.
In vitro, using patient‑derived, chemotherapy‑resistant glioblastoma cells from the Mayo Clinic, HITMAN eliminated 52.2% of the cancer cells—over five times the efficacy of the standard drug temozolomide (TMZ)—while leaving neurons and astrocytes unharmed. When these cells were orthotopically implanted into mouse brains, HITMAN markedly suppressed tumor growth, extending median survival by more than 50% with no detectable toxicity to major organs (kidney, liver, spleen, lung, heart).
The localized electric field disrupts the cells’ intrinsic bioelectric currents, triggering protein unfolding, membrane damage, endoplasmic reticulum stress, and other antitumor mechanisms that culminate in cell death. Cancer cells are preferentially targeted because of their high proliferation rate, elevated protein‑folding demand, and abnormal membrane and organelle composition. Control experiments confirmed that neither the nanoantennas alone nor the magnetic field alone produced the observed effects, underscoring the necessity of their combined activation. Colony formation dropped from 112‑150 in controls to just 26 in the HITMAN group, indicating strong potential to reduce recurrence and metastasis.
Clinically, the ~150 nm nanoantennas could be injected through the skull. Moreover, a 2025 “circulatronics” platform developed by the same lab may enable arm‑injection delivery, allowing the devices to cross the blood‑brain barrier and home to the tumor site, further simplifying the procedure.
In summary, HITMAN offers a minimally invasive, spatially precise, and clinically translatable therapy for drug‑resistant glioblastoma, addressing a critical unmet need in neuro‑oncology.
Review: By ingeniously coupling magnetostrictive actuation with piezoelectric conversion, this approach delivers non‑invasive, site‑specific electric fields to eradicate hard‑to‑treat brain tumors, and it merits close attention as it moves toward clinical trials.